In recent trading session, Bristol-Myers Squibb Co (NYSE:BMY) saw 5.59 million shares changing hands at last check today with its beta currently measuring 0.45. Company’s recent per share price level of $48.49 trading at -$0.04 or -0.07% at last check today assigns it a market valuation of $98.68B. That most recent trading price of BMY’s stock is at a discount of -30.6% from its 52-week high price of $63.33 and is indicating a premium of 18.85% from its 52-week low price of $39.35. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 16.87 million shares which gives us an average trading volume of 13.11 million if we extend that period to 3-months.
For Bristol-Myers Squibb Co (BMY), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 2.64. Splitting up the data highlights that, out of 14 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 9 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 1.69 in the current quarter.
Bristol-Myers Squibb Co (NYSE:BMY) trade information
Upright in the red during last session for losing -0.07%, in the last five days BMY remained trading in the red while hitting it’s week-highest on Thursday, 04/17/25 when the stock touched $48.49 price level, adding 3.19% to its value on the day. Bristol-Myers Squibb Co’s shares saw a change of -14.26% in year-to-date performance and have moved -1.75% in past 5-day. Bristol-Myers Squibb Co (NYSE:BMY) showed a performance of -18.07% in past 30-days. Number of shares sold short was 29.4 million shares which calculate 2.27 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 61 to the stock, which implies a rise of 20.51% to its recent value today. Analysts have been projecting 61 as a low price target for the stock while placing it at a high target of 61. It follows that stock’s current price would drop -25.8% in reaching the projected high whereas dropping to the targeted low would mean a loss of -25.8% for stock’s current value.
Bristol-Myers Squibb Co (BMY) estimates and forecasts
This year revenue growth is estimated to fall -5.35% from the last financial year’s standing.
15 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 11.33B for the same. And 15 analysts are in estimates of company making revenue of 11.59B in the next quarter. Company posted 12.2B and 11.89B of sales in current and next quarters respectively a year earlier.
In 2025, company’s earnings growth rate is likely to be around 485.70% while estimates for its earnings growth in next 5 years are of 72.74%.
BMY Dividends
Bristol-Myers Squibb Co is more likely to be releasing its next quarterly report on 2025-Feb-05 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 5.03%, the share has a forward dividend of 2.44 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 3.52%.
Bristol-Myers Squibb Co (NYSE:BMY)’s Major holders
Insiders are in possession of 0.07% of company’s total shares while institution are holding 80.58 percent of that, with stock having share float percentage of 80.64%. Investors also watch the number of corporate investors in a company very closely, which is 80.58% institutions for Bristol-Myers Squibb Co that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at BMY for having 186.57 million shares of worth $7.75 billion. And as of 2024-06-30, it was holding 9.2043 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 158.66 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.8273 of outstanding shares, having a total worth of $6.59 billion.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 63.59 shares of worth $3.06 billion or 3.13% of the total outstanding shares. The later fund manager was in possession of 54.9 shares on Dec 31, 2024 , making its stake of worth around $2.64 billion in the company or a holder of 2.70% of company’s stock.
